Overview

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
Phase:
PHASE3
Details
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Treatments:
entacapone